{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:10:01Z","timestamp":1792199401200,"version":"4.4.0"},"reference-count":204,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T00:00:00Z","timestamp":1661644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"King Abdullah University of Science and Technology (KAUST), Thuwal, Jeddah, Saudi Arabia"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Cancer is a complex disease, and its treatment is a big challenge, with variable efficacy of conventional anticancer drugs. A two-drug cocktail hybrid approach is a potential strategy in recent drug discovery that involves the combination of two drug pharmacophores into a single molecule. The hybrid molecule acts through distinct modes of action on several targets at a given time with more efficacy and less susceptibility to resistance. Thus, there is a huge scope for using hybrid compounds to tackle the present difficulties in cancer medicine. Recent work has applied this technique to uncover some interesting molecules with substantial anticancer properties. In this study, we report data on numerous promising hybrid anti-proliferative\/anti-tumor agents developed over the previous 10 years (2011\u20132021). It includes quinazoline, indole, carbazole, pyrimidine, quinoline, quinone, imidazole, selenium, platinum, hydroxamic acid, ferrocene, curcumin, triazole, benzimidazole, isatin, pyrrolo benzodiazepine (PBD), chalcone, coumarin, nitrogen mustard, pyrazole, and pyridine-based anticancer hybrids produced via molecular hybridization techniques. Overall, this review offers a clear indication of the potential benefits of merging pharmacophoric subunits from multiple different known chemical prototypes to produce more potent and precise hybrid compounds. This provides valuable knowledge for researchers working on complex diseases such as cancer.<\/jats:p>","DOI":"10.3390\/ph15091071","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T22:53:42Z","timestamp":1661813622000},"page":"1071","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":231,"title":["Concept of Hybrid Drugs and Recent Advancements in Anticancer Hybrids"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6129-0169","authenticated-orcid":false,"given":"Ankit Kumar","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda 154001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8035-5984","authenticated-orcid":false,"given":"Adarsh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda 154001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshwardhan","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda 154001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6486-0104","authenticated-orcid":false,"given":"Pankaj","family":"Sonawane","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda 154001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshali","family":"Paliwal","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda 154001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Thareja","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda 154001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6160-9755","authenticated-orcid":false,"given":"Prateek","family":"Pathak","sequence":"additional","affiliation":[{"name":"Laboratory of Computational Modeling of Drugs, Higher Medical and Biological School, South Ural State University, 454008 Chelyabinsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2573-4831","authenticated-orcid":false,"given":"Maria","family":"Grishina","sequence":"additional","affiliation":[{"name":"Laboratory of Computational Modeling of Drugs, Higher Medical and Biological School, South Ural State University, 454008 Chelyabinsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"Jaremko","sequence":"additional","affiliation":[{"name":"Smart-Health Initiative (SHI) and Red Sea Research Center (RSRC), Division of Biological and Environmental Sciences and Engineering (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9231-3850","authenticated-orcid":false,"given":"Abdul-Hamid","family":"Emwas","sequence":"additional","affiliation":[{"name":"Core Laboratories, King Abdullah University of Science and Technology (KAUST), Thuwal 23955, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8386-9825","authenticated-orcid":false,"given":"Jagat Pal","family":"Yadav","sequence":"additional","affiliation":[{"name":"Bioorganic and Medicinal Chemistry Research Laboratory, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj 211007, India"},{"name":"Department of Pharmacology, Kamla Nehru Institute of Management and Technology, Faridipur, Sultanpur 228118, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6653-7335","authenticated-orcid":false,"given":"Amita","family":"Verma","sequence":"additional","affiliation":[{"name":"Bioorganic and Medicinal Chemistry Research Laboratory, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj 211007, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7401-6254","authenticated-orcid":false,"given":"Habibullah","family":"Khalilullah","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry and Pharmacognosy, Unaizah College of Pharmacy, Qassim University, Unayzah 51911, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4284-2826","authenticated-orcid":false,"given":"Pradeep","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda 154001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00044-014-1196-5","article-title":"A review on pharmacophoric designs of antiproliferative agents","volume":"24","author":"Rana","year":"2015","journal-title":"Med. Chem. Res."},{"key":"ref_2","first-page":"000107","article-title":"An overview: Several causes of breast cancer","volume":"2","author":"Kori","year":"2018","journal-title":"Epidemol. Int. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jcrpr.2017.07.001","article-title":"Review of cancer from perspective of molecular","volume":"4","author":"Hassanpour","year":"2017","journal-title":"J. Cancer Res. Pract."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Cancer J. Clin."},{"key":"ref_5","first-page":"58","article-title":"Cancer care: Challenges in the developing world","volume":"1","author":"Philip","year":"2018","journal-title":"Cancer Res. Treat."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"8836","DOI":"10.1039\/C5CS00705D","article-title":"The challenges for cancer chemoprevention","volume":"44","author":"Penny","year":"2015","journal-title":"Chem. Soc. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.clinthera.2016.03.026","article-title":"Current challenges in cancer treatment","volume":"38","author":"Zugazagoitia","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_9","first-page":"ed16","article-title":"The difficulties in cancer treatment","volume":"6","author":"Chakraborty","year":"2012","journal-title":"Ecancermedicalscience"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/17460441.2021.1850686","article-title":"Have molecular hybrids delivered effective anticancer treatments and what should future drug discovery focus on?","volume":"16","author":"Shalini","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"112904","DOI":"10.1016\/j.ejmech.2020.112904","article-title":"Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors","volume":"209","author":"Bass","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1517\/17460440903341705","article-title":"Promise and challenges in drug discovery and development of hybrid anticancer drugs","volume":"4","author":"Gediya","year":"2009","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1007\/s11164-019-03827-y","article-title":"Synthesis of some hybrid 7-hydroxy quinolinone derivatives as anti breast cancer drugs","volume":"45","author":"Moustafa","year":"2019","journal-title":"Res. Chem. Intermed."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ejmech.2014.03.018","article-title":"Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids","volume":"77","author":"Nepali","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.2174\/092986711795328355","article-title":"Hybrid molecules incorporating natural products: Applications in cancer therapy, neurodegenerative disorders and beyond","volume":"18","author":"Decker","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejmech.2017.07.033","article-title":"Recent advances (2015\u20132016) in anticancer hybrids","volume":"142","author":"Kerru","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Szumilak, M., Wiktorowska-Owczarek, A., and Stanczak, A. (2021). Hybrid drugs\u2014A strategy for overcoming anticancer drug resistance?. Molecules, 26.","DOI":"10.3390\/molecules26092601"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"28313","DOI":"10.1039\/C6RA24662A","article-title":"Small hybrid heteroaromatics: Resourceful biological tools in cancer research","volume":"7","author":"Abbot","year":"2017","journal-title":"RSC Adv."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1517\/17460441.2013.798296","article-title":"Advances in the development of hybrid anticancer drugs","volume":"8","author":"Fortin","year":"2013","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ejmech.2016.08.039","article-title":"Hybrid molecules: The privileged scaffolds for various pharmaceuticals","volume":"124","author":"Mishra","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.2174\/1568026617666170707124126","article-title":"Multi-targeted anticancer agents","volume":"17","author":"Zheng","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e1461","DOI":"10.1002\/wsbm.1461","article-title":"Hybrid modeling frameworks of tumor development and treatment","volume":"12","author":"Chamseddine","year":"2020","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ejmech.2018.03.076","article-title":"An overview of quinazolines: Pharmacological significance and recent developments","volume":"151","author":"Alagarsamy","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejmech.2019.03.004","article-title":"Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry","volume":"170","author":"Das","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ejmech.2014.11.010","article-title":"Design, synthesis and biological evaluation of 6-(nitroimidazole-1H-alkyloxyl)-4-anilinoquinazolines as efficient EGFR inhibitors exerting cytotoxic effects both under normoxia and hypoxia","volume":"89","author":"Cheng","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1016\/j.bmcl.2017.08.035","article-title":"Quinazoline-1-deoxynojirimycin hybrids as high active dual inhibitors of EGFR and \u03b1-glucosidase","volume":"27","author":"Zhang","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ejmech.2016.09.039","article-title":"Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2","volume":"125","author":"Zhang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ejmech.2016.07.006","article-title":"6-Aryl substituted 4-(4-cyanomethyl) phenylamino quinazolines as a new class of isoform-selective PI3K-alpha inhibitors","volume":"122","author":"Yadav","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ejmech.2018.01.081","article-title":"Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3K\u03b1","volume":"146","author":"Ding","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.bmc.2018.02.015","article-title":"Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3K\u03b1 inhibition","volume":"26","author":"Fan","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1021\/acsomega.7b00310","article-title":"Synthesis of novel hybrids of quinazoline and artemisinin with high activities against Plasmodium falciparum, human cytomegalovirus, and leukemia cells","volume":"2","author":"Reiter","year":"2017","journal-title":"ACS Omega"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1016\/j.bmcl.2018.08.039","article-title":"Discovery and lead identification of quinazoline-based BRD4 inhibitors","volume":"28","author":"Yang","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Lee, H.A., Hyun, S.A., Byun, B., Chae, J.H., and Kim, K.S. (2018). Electrophysiological mechanisms of vandetanib-induced cardiotoxicity: Comparison of action potentials in rabbit Purkinje fibers and pluripotent stem cell-derived cardiomyocytes. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0195577"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Cheng, C.C., Chang, J., Huang, S.C.C., Lin, H.C., Ho, A.S., Lim, K.H., Chang, C.C., Huang, L., Chang, Y.C., and Chang, Y.F. (2017). YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0182149"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Han, W., Pan, H., Chen, Y., Sun, J., Wang, Y., Li, J., Ge, W., Feng, L., Lin, X., and Wang, X. (2011). EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018691"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cbi.2019.02.020","article-title":"Fisetin suppresses migration, invasion and stem-cell-like phenotype of human non-small cell lung carcinoma cells via attenuation of epithelial to mesenchymal transition","volume":"303","author":"Tabasum","year":"2019","journal-title":"Chem. Biol. Interact."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1021\/acs.chemrestox.5b00524","article-title":"P450 3A-catalyzed O-dealkylation of lapatinib induces mitochondrial stress and activates Nrf2","volume":"29","author":"Eno","year":"2016","journal-title":"Chem. Res. Toxicol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1172\/JCI94509","article-title":"STAT5B N642H is a driver mutation for T cell neoplasia","volume":"128","author":"Pham","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s12672-016-0257-2","article-title":"CUDC-101, a novel inhibitor of full-length androgen receptor (flAR) and androgen receptor variant 7 (AR-V7) activity: Mechanism of action and in vivo efficacy","volume":"7","author":"Sun","year":"2016","journal-title":"Horm. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.taap.2016.09.010","article-title":"Nrf2 but not autophagy inhibition is associated with the survival of wild-type epidermal growth factor receptor non-small cell lung cancer cells","volume":"310","author":"Zhou","year":"2016","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"103021","DOI":"10.1016\/j.bioorg.2019.103021","article-title":"Medicinal chemistry of indole derivatives: Current to future therapeutic prospectives","volume":"89","author":"Kumari","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejmech.2018.02.065","article-title":"Indole in the target-based design of anticancer agents: A versatile scaffold with diverse mechanisms","volume":"150","author":"Dadashpour","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1021\/ml300366t","article-title":"Development of N-hydroxycinnamamide-based histone deacetylase inhibitors with an indole-containing cap group","volume":"4","author":"Zhang","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1021\/jm401877m","article-title":"Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1\/3 dual inhibitors with potent oral antitumor activity","volume":"57","author":"Li","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ejmech.2014.08.020","article-title":"Indole-3-ethylsulfamoylphenylacrylamides: Potent histone deacetylase inhibitors with anti-inflammatory activity","volume":"85","author":"Mehndiratta","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejmech.2013.08.018","article-title":"Identification and characterization of novel indole based small molecules as anticancer agents through SIRT1 inhibition","volume":"69","author":"Panathur","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.5012\/bkcs.2014.35.7.2123","article-title":"3, 5-bis (aminopyrimidinyl) indole derivatives: Synthesis and evaluation of pim kinase inhibitory activities","volume":"35","author":"Lee","year":"2014","journal-title":"Bull. Korean Chem. Soc."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bioorg.2017.09.005","article-title":"New indole-based chalconoids as tubulin-targeting antiproliferative agents","volume":"75","author":"Mirzaei","year":"2017","journal-title":"Bioorg. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.bmcl.2015.11.092","article-title":"Synthesis and cytotoxic activity of novel hexahydropyrrolo [2, 3-b] indole imidazolium salts","volume":"26","author":"Zhou","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1016\/j.bmcl.2014.09.085","article-title":"Synthesis and identification of \u03b1-cyano bis (indolyl) chalcones as novel anticancer agents","volume":"24","author":"Kumar","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1039\/C7NJ04964A","article-title":"Design, synthesis, anti-proliferative evaluation and docking studies of 1 H-1, 2, 3-triazole tethered ospemifene\u2013isatin conjugates as selective estrogen receptor modulators","volume":"42","author":"Kumar","year":"2018","journal-title":"New J. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.1039\/C9RA00744J","article-title":"Diastereoselective approach to rationally design tetrahydro-\u03b2-carboline\u2013isatin conjugates as potential SERMs against breast cancer","volume":"9","author":"Sharma","year":"2019","journal-title":"RSC Adv."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2217\/fon.09.18","article-title":"Current status of cediranib: The rapid development of a novel anti-angiogenic therapy","volume":"5","author":"Lindsay","year":"2009","journal-title":"Future Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41419-020-02749-7","article-title":"Anlotinib suppresses tumor progression via blocking the VEGFR2\/PI3K\/AKT cascade in intrahepatic cholangiocarcinoma","volume":"11","author":"Song","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.febslet.2012.02.037","article-title":"Regulation of EMT by TGF\u03b2 in cancer","volume":"586","author":"Heldin","year":"2012","journal-title":"FEBS Lett."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1124\/mol.112.079624","article-title":"Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway","volume":"82","author":"Yaseen","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1158\/1535-7163.MCT-06-0125","article-title":"Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma","volume":"6","author":"Kato","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ejmech.2015.02.059","article-title":"Biological potential of carbazole derivatives","volume":"94","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1080\/14756366.2019.1640692","article-title":"Carbazole scaffolds in cancer therapy: A review from 2012 to 2018","volume":"34","author":"Issa","year":"2019","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"13101","DOI":"10.1038\/srep13101","article-title":"Synthesis and antitumor activity of novel N-substituted carbazole imidazolium salt derivatives","volume":"5","author":"Liu","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Mongre, R.K., Mishra, C.B., Prakash, A., Jung, S., Lee, B.S., Kumari, S., Hong, J.T., and Lee, M.S. (2019). Novel carbazole-piperazine hybrid small molecule induces apoptosis by targeting BCL-2 and inhibits tumor progression in lung adenocarcinoma in vitro and xenograft mice model. Cancers, 11.","DOI":"10.3390\/cancers11091245"},{"key":"ref_62","unstructured":"Rawjewski, R.A. (2012). Formulations of Indole-3-Carbinol Derived Antitumor Agents with Increased Oral Bioavailability. (13\/263,838), U.S. Patent."},{"key":"ref_63","unstructured":"Tucker, J., Sviridov, S., Brodsky, L., Burkhart, C., Purmal, A., Gurova, K., and Gudkov, A. (2015). Carbazole Compounds and Therapeutic Uses of the Compounds. (8,765,738), U.S. Patent."},{"key":"ref_64","unstructured":"Narayanan, R., Miller, D.D., Ponnusamy, T., Hwang, D.J., Pagadala, J., Duke, C.B., Coss, C.C., Dalton, J.T., and He, Y. (2017). Selective Androgen Receptor Degrader (SARD) Ligands and Methods of Use Thereof. (9,815,776 B2), U.S. Patent."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.biopha.2017.03.018","article-title":"Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection","volume":"90","author":"Chirino","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1182\/bloodadvances.2017011080","article-title":"Midostaurin: Its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis","volume":"2","author":"Stone","year":"2018","journal-title":"Blood Adv."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.tiv.2009.06.027","article-title":"Oral small-molecule tyrosine kinase inhibitor midostaurin (PKC412) inhibits growth and induces megakaryocytic differentiation in human leukemia cells","volume":"23","author":"Huang","year":"2009","journal-title":"Toxicol. Vitr."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.toxlet.2018.04.010","article-title":"Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes","volume":"291","author":"Zhang","year":"2018","journal-title":"Toxicol. Lett."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.4161\/cbt.4.11.2286","article-title":"Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor re-growth","volume":"4","author":"Hawkins","year":"2005","journal-title":"Cancer Biol. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13065-018-0406-5","article-title":"Therapeutic potential of heterocyclic pyrimidine scaffolds","volume":"12","author":"Kumar","year":"2018","journal-title":"Chem. Cent. J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/1574892809666140917104502","article-title":"Anticancer pyrimidines in diverse scaffolds: A review of patent literature","volume":"10","author":"Kaur","year":"2015","journal-title":"Recent Pat. Anticancer. Drug Discov."},{"key":"ref_72","unstructured":"Combs, A.P., Li, Y.L., Mei, S., and Yue, E.W. (2015). Substituted Diamino-Pyrimidine and Diamino-Pyridine Derivatives as PI3K Inhibitors. (9,108,984), U.S. Patent."},{"key":"ref_73","unstructured":"Boloor, A., Cheung, M., Harris, P.A., Hinkle, K., Laudeman, C.P., Stafford, J.A., and Veal, J.M. (2012). Chemical Compounds. (GB201201758D0), Patent."},{"key":"ref_74","unstructured":"Hogberg, M., Dahlstedt, E., Smitt, O., and Johansson, T. (2012). Novel Pyrimidine Derivatives. (WO2012127032), Patent."},{"key":"ref_75","unstructured":"Liu, J., Mao, L., Wang, X., Xu, X., and Zhao, L. (2012). Pyrazolopyrimidine Derivatives and Uses as Anticancer Agents. (WO2012\/097196 A), Patent."},{"key":"ref_76","unstructured":"Tanaka, M., Zhang, C., Shokat, K.M., Burlingame, A.L., Hansen, K., Bateman, R.L., and DiMagno, S.G. (2013). Pyrazolo Pyrimidine Derivatives and Methods of Use Thereof. (US201313862348A), Patent."},{"key":"ref_77","unstructured":"Liang, C. (2013). mTOR Selective Kinase Inhibitors. (US20130072481), U.S. Patent."},{"key":"ref_78","unstructured":"Dorsch, D., Hoelzemann, G., Schiemann, K., and Wegener, A. (2013). Triazolo [4, 5-d] Pyrimidine Derivatives. (WO2013110309A1), Patent."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1016\/j.ejmech.2011.05.037","article-title":"Synthesis and antitumor activity of new sulfonamide derivatives of thiadiazolo [3, 2-a] pyrimidines","volume":"46","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ejmech.2013.08.052","article-title":"Synthesis, structure\u2013activity relationship and biological evaluation of 2, 4, 5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents","volume":"70","author":"Shao","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejmech.2014.06.027","article-title":"Synthesis and antitumor activity of pyrido [2, 3-d] pyrimidine and pyrido [2, 3-d] [1, 2, 4] triazolo [4, 3-a] pyrimidine derivatives that induce apoptosis through G1 cell-cycle arrest","volume":"83","author":"Fares","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1016\/j.ejmech.2011.05.011","article-title":"Synthesis of novel alkyltriazole tagged pyrido [2, 3-d] pyrimidine derivatives and their anticancer activity","volume":"46","author":"Kurumurthy","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1016\/j.bmcl.2014.04.084","article-title":"Synthesis, cytotoxicity, antimicrobial and anti-biofilm activities of novel pyrazolo [3, 4-b] pyridine and pyrimidine functionalized 1, 2, 3-triazole derivatives","volume":"24","author":"Nagender","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"9658","DOI":"10.1016\/j.tet.2012.09.054","article-title":"One-pot synthesis and antiproliferative evaluation of pyrazolo [3, 4-d] pyrimidine derivatives","volume":"68","author":"Huang","year":"2012","journal-title":"Tetrahedron"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cbi.2018.02.018","article-title":"5-chloro-N4-(2-(isopropylsulfonyl) phenyl)-N2-(2-methoxy-4-(4-((4-methylpiperazin-1-yl) methyl)-1H-1, 2, 3-triazol-1-yl) phenyl) pyrimidine-2, 4-diamine (WY-135), a novel ALK inhibitor, induces cell cycle arrest and apoptosis through inhibiting ALK and its downstream pathways in Karpas299 and H2228 cells","volume":"284","author":"Han","year":"2018","journal-title":"Chem. Biol. Interact."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5906","DOI":"10.1038\/ncomms6906","article-title":"Rb and FZR1\/Cdh1 determine CDK4\/6-cyclin D requirement in C. elegans and human cancer cells","volume":"6","author":"The","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"11365","DOI":"10.1073\/pnas.1411701111","article-title":"Blockade of oncogenic I\u03baB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors","volume":"111","author":"Ceribelli","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"114761","DOI":"10.1016\/j.taap.2019.114761","article-title":"Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes","volume":"383","author":"Matsui","year":"2019","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejmech.2018.10.035","article-title":"Quinoline and quinolone dimers and their biological activities: An overview","volume":"161","author":"Chu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"gix065","DOI":"10.1093\/gigascience\/gix065","article-title":"De novo genome assembly of Camptotheca acuminata, a natural source of the anticancer compound camptothecin","volume":"6","author":"Zhao","year":"2017","journal-title":"GigaScience"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.ejmech.2014.07.044","article-title":"A review on anticancer potential of bioactive heterocycle quinoline","volume":"97","author":"Afzal","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ejmech.2015.10.022","article-title":"The synthesis of indolo [2, 3-b] quinoline derivatives with a guanidine group: Highly selective cytotoxic agents","volume":"105","author":"Sidoryk","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1007\/s00044-015-1388-7","article-title":"Synthesis and anticancer activity of novel tetrahydroquinoline and tetrahydropyrimidoquinoline derivatives","volume":"24","author":"Gedawy","year":"2015","journal-title":"Med. Chem. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1016\/j.ejmech.2011.02.063","article-title":"Antineoplastic activity of the thiazolo [5, 4-b] quinoline derivative D3CLP in K-562 cells is mediated through effector caspases activation","volume":"46","author":"Solano","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"6103","DOI":"10.1016\/j.bmcl.2012.08.032","article-title":"New derivatives of 11-methyl-6-[2-(dimethylamino) ethyl]-6H-indolo [2, 3-b] quinoline as cytotoxic DNA topoisomerase II inhibitors","volume":"22","author":"Luniewski","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/14756366.2019.1605364","article-title":"Design, synthesis, and anticancer evaluation of novel quinoline derivatives of ursolic acid with hydrazide, oxadiazole, and thiadiazole moieties as potent MEK inhibitors","volume":"34","author":"Jin","year":"2019","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1038\/s41598-019-42816-4","article-title":"Examination of novel 4-aminoquinoline derivatives designed and synthesized by a hybrid pharmacophore approach to enhance their anticancer activities","volume":"9","author":"Solomon","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejmech.2014.08.054","article-title":"Highly potent anti-proliferative effects of a gallium (III) complex with 7-chloroquinoline thiosemicarbazone as a ligand: Synthesis, cytotoxic and antimalarial evaluation","volume":"86","author":"Kumar","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.2147\/CMAR.S188316","article-title":"Lenvatinib, a molecule with versatile application: From preclinical evidence to future development in anticancer treatment","volume":"11","author":"Capozzi","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.tiv.2017.01.014","article-title":"Application of a nonradioactive assay for high throughput screening for inhibition of thyroid hormone uptake via the transmembrane transporter MCT8","volume":"40","author":"Dong","year":"2017","journal-title":"Toxicol. Vitr."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12935-019-0925-8","article-title":"The diverse mechanisms and anticancer potential of naphthoquinones","volume":"19","author":"Pereyra","year":"2019","journal-title":"Cancer Cell Int."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0891-5849(89)90162-7","article-title":"Free radical formation by antitumor quinones","volume":"6","author":"Powis","year":"1989","journal-title":"Free Radic. Biol. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ejmech.2014.10.055","article-title":"Anthraquinone\u2013chalcone hybrids: Synthesis, preliminary antiproliferative evaluation and DNA-interaction studies","volume":"89","author":"Debeljak","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"27502","DOI":"10.1039\/C5RA00154D","article-title":"Design, synthesis, and anticancer activities of new compounds bearing the quinone\u2013pyran\u2013lactone tricyclic pharmacophore","volume":"5","author":"Jiang","year":"2015","journal-title":"RSC Adv."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1039\/C7MD00067G","article-title":"Imidazoles as potential anticancer agents","volume":"8","author":"Ali","year":"2017","journal-title":"Med. Chem. Comm."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s00044-013-0760-8","article-title":"Synthesis and cytotoxic activity of novel hybrid compounds between 2-alkylbenzofuran and imidazole","volume":"23","author":"Wan","year":"2014","journal-title":"Med. Chem. Res."},{"key":"ref_107","first-page":"268","article-title":"A review on \u201cImidazoles\u201d: Their chemistry and pharmacological potentials","volume":"3","author":"Bhatnagar","year":"2011","journal-title":"Int. J. Pharm. Tech. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00044-010-9472-5","article-title":"Biological importance of imidazole nucleus in the new millennium","volume":"20","author":"Narasimhan","year":"2011","journal-title":"Med. Chem. Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1016\/j.bmcl.2012.02.094","article-title":"Design, synthesis and cytotoxic activities of novel hybrid compounds between 2-phenylbenzofuran and imidazole","volume":"22","author":"Yang","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1016\/j.bmcl.2013.06.001","article-title":"Synthesis and cytotoxic activities of novel hybrid 2-phenyl-3-alkylbenzofuran and imidazole\/triazole compounds","volume":"23","author":"Chen","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Al-Blewi, F., Shaikh, S.A., Naqvi, A., Aljohani, F., Aouad, M.R., Ihmaid, S., and Rezki, N. (2021). Design and synthesis of novel imidazole derivatives possessing triazole pharmacophore with potent anticancer activity, and in silico ADMET with GSK-3\u03b2 molecular docking investigations. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22031162"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.bmcl.2019.02.021","article-title":"Artemisinin-indole and artemisinin-imidazole hybrids: Synthesis, cytotoxic evaluation and reversal effects on multidrug resistance in MCF-7\/ADR cells","volume":"29","author":"Hu","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1039\/c2ra20376f","article-title":"Synthesis and cytotoxic activities of novel hybrid compounds of imidazole scaffold-based 2-substituted benzofurans","volume":"2","author":"Song","year":"2012","journal-title":"RSC Adv."},{"key":"ref_114","first-page":"e553WCRJ","article-title":"Overview of FDA-approved anti cancer drugs used for targeted therapy","volume":"2","author":"Rainone","year":"2015","journal-title":"WCRJ"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Sun, J., Wei, Q., Zhou, Y., Wang, J., Liu, Q., and Xu, H. (2017). A systematic analysis of FDA-approved anticancer drugs. BMC Syst. Biol., 11.","DOI":"10.1186\/s12918-017-0464-7"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3233\/BD-201063","article-title":"Mini review: The FDA-approved prescription drugs that target the MAPK signaling pathway in women with breast cancer","volume":"40","author":"Keivan","year":"2021","journal-title":"Breast Dis."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Tan, H.W., Mo, H.Y., Lau, A.T., and Xu, Y.M. (2018). Selenium species: Current status and potentials in cancer prevention and therapy. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20010075"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"112864","DOI":"10.1016\/j.ejmech.2020.112864","article-title":"Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF3) derivatives as potential anticancer agents","volume":"208","author":"He","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.freeradbiomed.2018.05.001","article-title":"Organic selenium compounds as potential chemotherapeutic agents for improved cancer treatment","volume":"127","author":"Gandin","year":"2018","journal-title":"Free Radic. Biol. Med."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Jardim, G.A., da Cruz, E.H., Valen\u00e7a, W.O., Lima, D.J., Cavalcanti, B.C., Pessoa, C., Rafique, J., Braga, A.L., Jacob, C., and da Silva J\u00fanior, E.N. (2017). Synthesis of selenium-quinone hybrid compounds with potential antitumor activity via Rh-catalyzed CH bond activation and click reactions. Molecules, 23.","DOI":"10.3390\/molecules23010083"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1039\/C8OB00875B","article-title":"The design, synthesis and evaluation of selenium-containing 4-anilinoquinazoline hybrids as anticancer agents and a study of their mechanism","volume":"16","author":"An","year":"2018","journal-title":"Org. Biomol. Chem."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"113531","DOI":"10.1016\/j.ejmech.2021.113531","article-title":"Bifunctional chiral selenium-containing 1, 4-diarylazetidin-2-ones with potent antitumor activities by disrupting tubulin polymerization and inducing reactive oxygen species production","volume":"221","author":"Tang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/cbdd.13900","article-title":"Synthesis and in vitro anticancer activities of selenium N-heterocyclic carbene compounds","volume":"98","author":"Huang","year":"2021","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","article-title":"The rediscovery of platinum-based cancer therapy","volume":"21","author":"Rottenberg","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2147\/DDDT.S119488","article-title":"Metal complexes in cancer therapy\u2013an update from drug design perspective","volume":"11","author":"Ndagi","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Ciarimboli, G. (2021). Anticancer Platinum Drugs Update. Biomolecules, 11.","DOI":"10.3390\/biom11111637"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jconrel.2021.05.022","article-title":"Methodology for characterization of platinum-based drug\u2019s targeted delivery nanosystems","volume":"335","author":"Zajda","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_128","first-page":"471","article-title":"Understanding and improving platinum anticancer drugs\u2013phenanthriplatin","volume":"34","author":"Johnstone","year":"2014","journal-title":"Anticancer Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"7817","DOI":"10.1021\/jm300879k","article-title":"Synthesis, aqueous reactivity, and biological evaluation of carboxylic acid ester-functionalized platinum\u2013acridine hybrid anticancer agents","volume":"55","author":"Graham","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"10317","DOI":"10.1021\/ic301374z","article-title":"Antitumor platinum (II) complexes containing platinum-based moieties of present platinum drugs and furoxan groups as nitric oxide donors: Synthesis, DNA interaction, and cytotoxicity","volume":"51","author":"Zhao","year":"2012","journal-title":"Inorg. Chem."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1039\/D0DT03194A","article-title":"Design, synthesis and biological evaluation of dihydro-2-quinolone platinum (IV) hybrids as antitumor agents displaying mitochondria injury and DNA damage mechanism","volume":"50","author":"Liu","year":"2021","journal-title":"Dalton Trans."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1039\/D0DT00424C","article-title":"Naproxen platinum (iv) hybrids inhibiting cycloxygenases and matrix metalloproteinases and causing DNA damage: Synthesis and biological evaluation as antitumor agents in vitro and in vivo","volume":"49","author":"Chen","year":"2020","journal-title":"Dalton Trans."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ejmech.2013.02.022","article-title":"Design, modeling, synthesis and biological activity evaluation of camptothecin-linked platinum anticancer agents","volume":"63","author":"Cincinelli","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fphar.2020.00343","article-title":"The drug-resistance mechanisms of five platinum-based antitumor agents","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00280-016-2976-z","article-title":"Platinum-based drugs: Past, present and future","volume":"77","author":"Dilruba","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bioorg.2016.03.008","article-title":"Design, synthesis and biological evaluation of novel hydroxamic acids bearing artemisinin skeleton","volume":"66","author":"Ha","year":"2016","journal-title":"Bioorg. Chem."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ejmech.2017.12.061","article-title":"Development of novel \u03b2-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells","volume":"144","author":"Ling","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bioorg.2017.03.005","article-title":"Design, synthesis, docking studies and biological evaluation of novel chalcone derivatives as potential histone deacetylase inhibitors","volume":"72","author":"Mohamed","year":"2017","journal-title":"Bioorg. Chem."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bmc.2016.10.006","article-title":"Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy","volume":"25","author":"Ding","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.arabjc.2015.10.007","article-title":"Exploration of novel 5\u2032(7\u2032)-substituted-2\u2032-oxospiro[1,3]dioxolane-2,3\u2032-indoline-based N-hydroxypropenamides as histone deacetylase inhibitors and antitumor agents","volume":"10","author":"Dung","year":"2017","journal-title":"Arab. J. Chem."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4103\/0019-5154.160511","article-title":"Vorinostat-An Overview","volume":"60","author":"Bubna","year":"2015","journal-title":"Indian J. Dermatol."},{"key":"ref_142","first-page":"296","article-title":"Panobinostat (Farydak): A Novel Option for the Treatment of Relapsed Or Relapsed and Refractory Multiple Myeloma","volume":"41","author":"Moore","year":"2016","journal-title":"Pharm. Ther."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1007\/s10637-018-0658-x","article-title":"Phase I\/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients","volume":"36","author":"Tak","year":"2018","journal-title":"Investig. New Drugs"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"978","DOI":"10.2174\/1385272823666190424142821","article-title":"Methods for Hydroxamic Acid Synthesis","volume":"23","author":"Alam","year":"2019","journal-title":"Curr. Org. Chem."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jorganchem.2010.11.021","article-title":"Ferrocene\u2013indole hybrids for cancer and malaria therapy","volume":"696","author":"Quirante","year":"2011","journal-title":"J. Organomet. Chem."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jorganchem.2013.08.043","article-title":"Synthesis, characterization and antitumor activity of novel ferrocene derivatives containing pyrazolyl-moiety","volume":"749","author":"Huang","year":"2014","journal-title":"J. Organomet. Chem."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00044-016-1509-y","article-title":"Synthesis and in vitro biological activities of ferrocenyl\u2013chalcone amides","volume":"25","author":"Smit","year":"2016","journal-title":"Med. Chem. Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"120968","DOI":"10.1016\/j.jorganchem.2019.120968","article-title":"Synthesis, characterization and antitumor activity of novel ferrocene-coumarin conjugates","volume":"902","author":"Wei","year":"2019","journal-title":"J. Organomet. Chem."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jorganchem.2016.04.011","article-title":"Ferrocenyl chalcogeno (sugar) triazole conjugates: Synthesis, characterization and anticancer properties","volume":"813","author":"Panaka","year":"2016","journal-title":"J. Organomet. Chem."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1016\/j.bmcl.2015.06.068","article-title":"Synthesis and anticancer activity of novel curcumin\u2013quinolone hybrids","volume":"25","author":"Raghavan","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.molstruc.2017.10.097","article-title":"Synthesis and characterization of curcumin-sulfonamide hybrids: Biological evaluation and molecular docking studies","volume":"1155","author":"Banuppriya","year":"2018","journal-title":"J. Mol. Struct."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1007\/s00044-016-1628-5","article-title":"Synthesis and antiproliferative studies of curcumin pyrazole derivatives","volume":"25","author":"Puneeth","year":"2016","journal-title":"Med. Chem. Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1016\/j.bmc.2013.06.053","article-title":"Exploring pyrimidine-substituted curcumin analogues: Design, synthesis and effects on EGFR signaling","volume":"21","author":"Qiu","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"7165","DOI":"10.1016\/j.bmc.2015.10.013","article-title":"Triazole linked mono carbonyl curcumin-isatin bifunctional hybrids as novel anti tubulin agents: Design, synthesis, biological evaluation and molecular modeling studies","volume":"23","author":"Sharma","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.bmcl.2014.12.087","article-title":"Design and synthesis of novel 1,2,3-triazole\u2013pyrimidine\u2013urea hybrids as potential anticancer agents","volume":"25","author":"Ma","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ejmech.2016.03.013","article-title":"Novel triazole hybrids of myrrhanone C, a natural polypodane triterpene: Synthesis, cytotoxic activity and cell based studies","volume":"114","author":"Chandrashekhar","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/jhet.2273","article-title":"Synthesis and In vitro Cytotoxic Activity of Novel Triazole-Isoxazole Derivatives","volume":"52","author":"Najafi","year":"2015","journal-title":"J. Heterocycl. Chem."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejmech.2012.12.046","article-title":"Design and synthesis of novel 1,2,3-triazole-dithiocarbamate hybrids as potential anticancer agents","volume":"62","author":"Duan","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.bmcl.2014.11.083","article-title":"Synthesis and anticancer evaluation of novel triazole linked N-(pyrimidin-2-yl)benzo[d]thiazol-2-amine derivatives as inhibitors of cell survival proteins and inducers of apoptosis in MCF-7 breast cancer cells","volume":"25","author":"Kumbhare","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"10089","DOI":"10.1021\/acsomega.0c00630","article-title":"Molecular Hybrids Integrated with Benzimidazole and Pyrazole Structural Motifs: Design, Synthesis, Biological Evaluation, and Molecular Docking Studies","volume":"5","author":"Sivaramakarthikeyan","year":"2020","journal-title":"ACS Omega"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1016\/j.bmcl.2014.06.050","article-title":"Synthesis and biological evaluation of novel pyrimidine\u2013benzimidazol hybrids as potential anticancer agents","volume":"24","author":"Shao","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ejmech.2016.08.029","article-title":"Synthesis and biological evaluation of new benzimidazole-thiazolidinedione hybrids as potential cytotoxic and apoptosis inducing agents","volume":"124","author":"Sharma","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1016\/j.bmc.2014.07.008","article-title":"Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2","volume":"22","author":"Shi","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"129351","DOI":"10.1016\/j.molstruc.2020.129351","article-title":"Design, synthesis, anticancer evaluation and binding mode studies of benzimidazole\/benzoxazole linked \u03b2-carboline derivatives","volume":"1226","author":"Sireesha","year":"2021","journal-title":"J. Mol. Struct."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s40265-017-0840-z","article-title":"Abemaciclib: First Global Approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.2217\/fon-2018-0883","article-title":"Veliparib: A new therapeutic option in ovarian cancer?","volume":"15","author":"Ghisoni","year":"2019","journal-title":"Future Oncol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.4143\/crt.2017.438","article-title":"Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05)","volume":"50","author":"Choi","year":"2018","journal-title":"Cancer Res. Treat."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"e25992","DOI":"10.1097\/MD.0000000000025992","article-title":"Clinical efficacy and safety of nazartinib for epidermal growth factor receptor mutated non-small cell lung cancer: Study protocol for a prospective, multicenter, open-label","volume":"100","author":"Cui","year":"2021","journal-title":"Medicine"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.bionut.2013.04.001","article-title":"Design, synthesis and biological evaluation of some isatin-linked chalcones as novel anti-breast cancer agents: A molecular hybridization approach","volume":"3","author":"Karthikeyan","year":"2013","journal-title":"Biomed. Prev. Nutr."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"104748","DOI":"10.1016\/j.bioorg.2021.104748","article-title":"Development of isatin-thiazolo [3, 2-a] benzimidazole hybrids as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: Synthesis, biological and molecular dynamics investigations","volume":"110","author":"Eldehna","year":"2021","journal-title":"Bioorg. Chem."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.2147\/DDDT.S140164","article-title":"Development; Therapy, Isatin-benzoazine molecular hybrids as potential antiproliferative agents: Synthesis and in vitro pharmacological profiling","volume":"11","author":"Eldehna","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1021\/acsmedchemlett.8b00596","article-title":"Investigating the anticancer activity of isatin\/dihydropyrazole hybrids","volume":"10","author":"Meleddu","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ejmech.2014.12.010","article-title":"Design, synthesis and QSAR study of certain isatin-pyridine hybrids as potential anti-proliferative agents","volume":"90","author":"Eldehna","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1016\/j.bmcl.2017.07.069","article-title":"Triazole tethered isatin-coumarin based molecular hybrids as novel antitubulin agents: Design, synthesis, biological investigation and docking studies","volume":"27","author":"Singh","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2147\/DDDT.S227862","article-title":"New Isatin\u2013Indole Conjugates: Synthesis, Characterization, and a Plausible Mechanism of Their in vitro Antiproliferative Activity","volume":"14","author":"Almomen","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4314\/epj.v31i2.1","article-title":"Synthesis and anticancer activity of new isatin-benzoic acid conjugates","volume":"31","author":"Panga","year":"2016","journal-title":"Ethiop. Pharm. J."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Cheke, R.S., Patil, V.M., Firke, S.D., Ambhore, J.P., Ansari, I.A., Patel, H.M., Shinde, S.D., Pasupuleti, V.R., Hassan, M.I., and Adnan, M.J.P. (2022). Therapeutic Outcomes of Isatin and Its Derivatives against Multiple Diseases: Recent Developments in Drug Discovery. Pharmaceuticals, 15.","DOI":"10.3390\/ph15030272"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Ferguson, L., Bhakta, S., Fox, K.R., Wells, G., and Brucoli, F.J.M. (2020). Synthesis and Biological Evaluation of a Novel C8-Pyrrolobenzodiazepine (PBD) Adenosine Conjugate. A Study on the Role of the PBD Ring in the Biological Activity of PBD-Conjugates. Molecules, 25.","DOI":"10.3390\/molecules25051243"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejmech.2012.01.014","article-title":"Hybrids of privileged structures benzothiazoles and pyrrolo [2, 1-c][1, 4] benzodiazepin-5-one, and diversity-oriented synthesis of benzothiazoles","volume":"50","author":"Bose","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.bmc.2011.12.003","article-title":"Design and synthesis of benzo [c, d] indolone-pyrrolobenzodiazepine conjugates as potential anticancer agents","volume":"20","author":"Kamal","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"105081","DOI":"10.1016\/j.bioorg.2021.105081","article-title":"Novel pyrrolo [2, 1-c][1, 4] benzodiazepine-3, 11-dione (PBD) derivatives as selective HDAC6 inhibitors to suppress tumor metastasis and invasion in vitro and in vivo","volume":"114","author":"Li","year":"2021","journal-title":"Bioorg. Chem."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"6854","DOI":"10.1016\/j.bmcl.2013.10.004","article-title":"Synthesis, DNA-binding abilities and anticancer activities of triazole-pyrrolo [2, 1-c][1, 4] benzodiazepines hybrid scaffolds","volume":"23","author":"Chen","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Al Zahrani, N.A., El-Shishtawy, R.M., Elaasser, M.M., and Asiri, A.M. (2020). Synthesis of novel chalcone-based phenothiazine derivatives as antioxidant and anticancer agents. Molecules, 25.","DOI":"10.3390\/molecules25194566"},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Ouyang, Y., Li, J., Chen, X., Fu, X., Sun, S., and Wu, Q. (2021). Chalcone Derivatives: Role in Anticancer Therapy. Biomolecules, 11.","DOI":"10.3390\/biom11060894"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"100762","DOI":"10.1016\/j.cdc.2021.100762","article-title":"Anticancer effects of chalcone-benzoxadiazole hybrids on KB human cancer cells","volume":"35","author":"Sivapriya","year":"2021","journal-title":"Chem. Data Collect."},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Alswah, M., Bayoumi, A.H., Elgamal, K., Elmorsy, A., Ihmaid, S., and Ahmed, H.E.A. (2017). Design, synthesis and cytotoxic evaluation of novel chalcone derivatives bearing triazolo [4, 3-a]-quinoxaline moieties as potent anticancer agents with dual EGFR kinase and tubulin polymerization inhibitory effects. Molecules, 23.","DOI":"10.3390\/molecules23010048"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1007\/s00044-021-02805-7","article-title":"New class of hybrids based on chalcone and melatonin: A promising therapeutic option for the treatment of colorectal cancer","volume":"30","author":"Yepes","year":"2021","journal-title":"Med. Chem. Res."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1080\/00397911.2021.1881124","article-title":"Synthesis and anticancer activity of chalcone\u2013quinoxalin conjugates","volume":"51","author":"Ma","year":"2021","journal-title":"Synth. Commun."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1016\/j.bmcl.2012.12.071","article-title":"Synthesis of new conjugated coumarin\u2013benzimidazole hybrids and their anticancer activity","volume":"23","author":"Paul","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"An, R., Hou, Z., Li, J.T., Yu, H.N., Mou, Y.H., and Guo, C. (2018). Design, synthesis and biological evaluation of novel 4-substituted coumarin derivatives as antitumor agents. Molecules, 23.","DOI":"10.3390\/molecules23092281"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.bmc.2016.12.019","article-title":"Design and synthesis of new coumarin hybrids and insight into their mode of antiproliferative action","volume":"25","author":"Elshemy","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jscs.2019.12.001","article-title":"Uracil-coumarin based hybrid molecules as potent anticancer and antibacterial agents","volume":"24","author":"Sanduja","year":"2020","journal-title":"J. Saudi Chem. Soc."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1007\/s00044-018-2140-x","article-title":"Design, synthesis and biological evaluation of novel furoxan-based coumarin derivatives as antitumor agents","volume":"27","author":"Zhang","year":"2018","journal-title":"Med. Chem. Res."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1021\/ml500141f","article-title":"Novel hybrids of natural oridonin-bearing nitrogen mustards as potential anticancer drug candidates","volume":"5","author":"Xu","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.molstruc.2016.04.058","article-title":"Thiazole-based nitrogen mustards: Design, synthesis, spectroscopic studies, DFT calculation, molecular docking, and antiproliferative activity against selected human cancer cell lines","volume":"1119","author":"Plech","year":"2016","journal-title":"J. Mol. Struct."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3109\/14756366.2011.604482","article-title":"Synthesis and cytotoxicity studies of bifunctional hybrids of nitrogen mustards with potential enzymes inhibitors based on melamine framework","volume":"27","author":"Kolesinska","year":"2012","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.steroids.2017.04.005","article-title":"Synthesis of androstene oxime-nitrogen mustard bioconjugates as potent antineoplastic agents","volume":"123","author":"Acharya","year":"2017","journal-title":"Steroids"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"12361","DOI":"10.1021\/acsomega.1c01604","article-title":"Design, synthesis, anticancer evaluation, enzymatic assays, and a molecular modeling study of novel pyrazole\u2013indole hybrids","volume":"6","author":"Hassan","year":"2021","journal-title":"ACS Omega"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bioorg.2015.08.006","article-title":"Design, synthesis, biological evaluation and molecular docking studies of novel benzofuran\u2013pyrazole derivatives as anticancer agents","volume":"63","author":"Anwar","year":"2015","journal-title":"Bioorg. Chem."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1080\/00397911.2021.1939058","article-title":"An efficient synthesis and evaluation of some novel quinazolinone-pyrazole hybrids as potential antiproliferative agents","volume":"51","author":"Abdalha","year":"2021","journal-title":"Synth. Commun."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"2000116","DOI":"10.1002\/ardp.202000116","article-title":"Design and synthesis of pyrazole\u2013pyrazoline hybrids as cancer-associated selective COX-2 inhibitors","volume":"354","author":"Akhtar","year":"2021","journal-title":"Archiv. Der. Pharmazie."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.bioorg.2018.01.007","article-title":"Synthesis of pyrazole acrylic acid based oxadiazole and amide derivatives as antimalarial and anticancer agents","volume":"77","author":"Verma","year":"2018","journal-title":"Bioorg. Chem."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1016\/j.bmcl.2014.07.094","article-title":"Design, synthesis and molecular modeling of biquinoline\u2013pyridine hybrids as a new class of potential EGFR and HER-2 kinase inhibitors","volume":"24","author":"Sangani","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/jhet.3764","article-title":"Synthesis and in vitro evaluation of novel tetralin-pyrazolo [3, 4-b] pyridine hybrids as potential anticancer agents","volume":"57","author":"Hamza","year":"2020","journal-title":"J. Heterocycl. Chem."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/9\/1071\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:19:12Z","timestamp":1760141952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/9\/1071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,28]]},"references-count":204,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["ph15091071"],"URL":"https:\/\/doi.org\/10.3390\/ph15091071","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,28]]}}}